EA
STML

Emerald Acquisition’s Stemline Therapeutics, Inc. STML Stock Holding History

Emerald Acquisition’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-19,139
Closed -$129K – 3081
2016
Q2 		$129K Buy
+19,139
New +$121K ﹤0.01% 2797

Other funds holding STML

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Emerald Acquisition's STML Position: Q3 2016 in Review

Emerald Acquisition sold out of Stemline Therapeutics, Inc. (STML) in Q3 2016, closing a stake of 19,139 shares — an estimated $129K sold.

Emerald Acquisition first reported a position in STML in Q2 2016 and held it in 1 quarter. The position peaked at $129K in Q2 2016. 69 funds tracked by Wall St. Rank hold STML as of Q3 2016.

  • Emerald Acquisition reported no remaining Stemline Therapeutics, Inc. position as of Q3 2016 after selling out during the quarter.
  • Emerald Acquisition sold 19,139 Stemline Therapeutics, Inc. shares in Q3 2016, an estimated $129K.
  • Emerald Acquisition first reported a position in Stemline Therapeutics, Inc. in Q2 2016 and held it in 1 quarter.
  • Emerald Acquisition's Stemline Therapeutics, Inc. position peaked at $129K in Q2 2016.
  • 69 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q3 2016.

Based on Emerald Acquisition's 13F filing for Q3 2016, filed 9 Nov 2016.